wikidoc - Recent changes [en]

ST2 cardiac biomarker

Gromeromd — Sat, 14 Nov 2026 21:40:14 GMT

The ST2/IL-33 Axis in Immune Cells in Inflammatory Diseases

← Older revision		Revision as of 21:40, 14 November 2026
(5 intermediate revisions by the same user not shown)
Line 28:		Line 28:
	ST2 is a member of the interleukin 1 receptor family. The ST2 protein has two isoforms and is directly implicated in the progression of cardiac disease: a soluble form (referred to as soluble ST2 or sST2) and a membrane-bound receptor form (referred to as the ST2 receptor or ST2L). When the myocardium is stretched, the ST2 gene is upregulated, increasing the concentration of circulating soluble ST2.<ref name="doi=10.1016/j.jchf.2012.10.002"/> The ligand for ST2 is the cytokine Interleukin-33(IL-33). Binding of IL-33 to the ST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counterbalanced by the level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of soluble ST2.		ST2 is a member of the interleukin 1 receptor family. The ST2 protein has two isoforms and is directly implicated in the progression of cardiac disease: a soluble form (referred to as soluble ST2 or sST2) and a membrane-bound receptor form (referred to as the ST2 receptor or ST2L). When the myocardium is stretched, the ST2 gene is upregulated, increasing the concentration of circulating soluble ST2.<ref name="doi=10.1016/j.jchf.2012.10.002"/> The ligand for ST2 is the cytokine Interleukin-33(IL-33). Binding of IL-33 to the ST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counterbalanced by the level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of soluble ST2.

	== Correlation with ~~mortality~~ ==		== Correlation with Mortality ==

	Published and peer-reviewed findings indicate that ST2 is a predictor of [[death\|mortality]] at presentation.<ref name="pmid18480207">{{cite journal \| author = Braunwald E \| title = Biomarkers in heart failure \| journal = N. Engl. J. Med. \| volume = 358 \| issue = 20 \| pages = 2148–59 \|date=May 2008 \| pmid = 18480207 \| doi = 10.1056/NEJMra0800239 }}</ref> Studies have shown patients with ST2 levels above a clinical threshold consistently have a much higher risk of mortality while, equally important, patients with ST2 levels below threshold have a very low risk of mortality.<ref name="pmid21178018">{{cite journal \|vauthors=Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP \| title = High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure \| journal = Circ Heart Fail \| volume = 4 \| issue = 2 \| pages = 180–7 \|date=March 2011 \| pmid = 21178018 \| pmc = 3163169 \| doi = 10.1161/CIRCHEARTFAILURE.110.958223 }}</ref><ref name="pmid22096031">{{cite journal \|vauthors=Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA \| title = Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| journal = Clin. Chem. \| volume = 58\| issue = 1\| pages = 257–66\|date=November 2011 \| pmid = 22096031 \| doi = 10.1373/clinchem.2011.173369 \| pmc = 4277435}}</ref> Although it has been shown that ST2 concentrations correlate with heart failure severity<ref name="pmid20804518">{{cite journal \|vauthors=Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C \| title = Interleukin family member ST2 and mortality in acute dyspnoea \| journal = J. Intern. Med. \| volume = 268 \| issue = 5 \| pages = 493–500 \|date=November 2010 \| pmid = 20804518 \| doi = 10.1111/j.1365-2796.2010.02263.x }}</ref> there is no level that perfectly separates patients with and without heart failure for disease diagnosis. However, as a prognostic marker it has been clearly shown that patients are at a higher risk of adverse outcomes when ST2 levels are above a cutoff value of 35 ng/mL.<ref name="pmid21178018"/>		Published and peer-reviewed findings indicate that ST2 is a predictor of [[death\|mortality]] at presentation.<ref name="pmid18480207">{{cite journal \| author = Braunwald E \| title = Biomarkers in heart failure \| journal = N. Engl. J. Med. \| volume = 358 \| issue = 20 \| pages = 2148–59 \|date=May 2008 \| pmid = 18480207 \| doi = 10.1056/NEJMra0800239 }}</ref> Studies have shown patients with ST2 levels above a clinical threshold consistently have a much higher risk of mortality while, equally important, patients with ST2 levels below threshold have a very low risk of mortality.<ref name="pmid21178018">{{cite journal \|vauthors=Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP \| title = High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure \| journal = Circ Heart Fail \| volume = 4 \| issue = 2 \| pages = 180–7 \|date=March 2011 \| pmid = 21178018 \| pmc = 3163169 \| doi = 10.1161/CIRCHEARTFAILURE.110.958223 }}</ref><ref name="pmid22096031">{{cite journal \|vauthors=Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA \| title = Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| journal = Clin. Chem. \| volume = 58\| issue = 1\| pages = 257–66\|date=November 2011 \| pmid = 22096031 \| doi = 10.1373/clinchem.2011.173369 \| pmc = 4277435}}</ref> Although it has been shown that ST2 concentrations correlate with heart failure severity<ref name="pmid20804518">{{cite journal \|vauthors=Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C \| title = Interleukin family member ST2 and mortality in acute dyspnoea \| journal = J. Intern. Med. \| volume = 268 \| issue = 5 \| pages = 493–500 \|date=November 2010 \| pmid = 20804518 \| doi = 10.1111/j.1365-2796.2010.02263.x }}</ref> there is no level that perfectly separates patients with and without heart failure for disease diagnosis. However, as a prognostic marker it has been clearly shown that patients are at a higher risk of adverse outcomes when ST2 levels are above a cutoff value of 35 ng/mL.<ref name="pmid21178018"/>
Line 38:		Line 38:
	ST2 is an active participant in the cardiac [[Ventricular remodeling\|remodeling]] pathway and could identify which patients will respond to [[Eplerenone]], or other therapies that reverse myocardial [[fibrosis]].<ref name="pmid20117403">{{cite journal \|vauthors=Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ \| title = Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction \| journal = J Am Coll Cardiol \| volume = 55 \| issue = 3 \| pages = 243–50 \|date=January 2010 \| pmid = 20117403 \| doi = 10.1016/j.jacc.2009.08.047}}</ref>		ST2 is an active participant in the cardiac [[Ventricular remodeling\|remodeling]] pathway and could identify which patients will respond to [[Eplerenone]], or other therapies that reverse myocardial [[fibrosis]].<ref name="pmid20117403">{{cite journal \|vauthors=Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ \| title = Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction \| journal = J Am Coll Cardiol \| volume = 55 \| issue = 3 \| pages = 243–50 \|date=January 2010 \| pmid = 20117403 \| doi = 10.1016/j.jacc.2009.08.047}}</ref>

	== Clinical ~~utility~~ ==		== Clinical Utility ==

	* ST2 has considerable prognostic value and is used as an aid for risk [[stratified medicine\|stratification]] in identifying patients who are at high risk of mortality and [http://en.wiktionary.org/wiki/rehospitalization rehospitalization] in patients diagnosed with heart failure.<ref name="pmid20875357">{{cite journal \|vauthors=Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J \| title = Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure \| journal = Rev Esp Cardiol \| volume = 63 \| issue = 10 \| pages = 1171–8 \|date=October 2010 \| pmid = 20875357 \| doi = 10.1016/s1885-5857(10)70231-0}}</ref>		* ST2 has considerable prognostic value and is used as an aid for risk [[stratified medicine\|stratification]] in identifying patients who are at high risk of mortality and [http://en.wiktionary.org/wiki/rehospitalization rehospitalization] in patients diagnosed with heart failure.<ref name="pmid20875357">{{cite journal \|vauthors=Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J \| title = Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure \| journal = Rev Esp Cardiol \| volume = 63 \| issue = 10 \| pages = 1171–8 \|date=October 2010 \| pmid = 20875357 \| doi = 10.1016/s1885-5857(10)70231-0}}</ref>
Line 45:		Line 45:
	* Repeated measurements of ST2 may aid in clinical decision-making.<ref name="pmid20875357"/><ref name="pmid18995177">{{cite journal \|vauthors=Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL \| title = Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure \| journal = J. Card. Fail. \| volume = 14 \| issue = 9 \| pages = 732–8 \|date=November 2008 \| pmid = 18995177 \| doi = 10.1016/j.cardfail.2008.06.415 }}</ref>		* Repeated measurements of ST2 may aid in clinical decision-making.<ref name="pmid20875357"/><ref name="pmid18995177">{{cite journal \|vauthors=Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL \| title = Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure \| journal = J. Card. Fail. \| volume = 14 \| issue = 9 \| pages = 732–8 \|date=November 2008 \| pmid = 18995177 \| doi = 10.1016/j.cardfail.2008.06.415 }}</ref>

	== The ST2 ~~test~~ ==		== The ST2 Test ==
	ST2 is measured by an [[immunoassay]], commercially marketed as the Presage ST2 Assay by Critical Diagnostics of San Diego, California.<ref name="urlCritical Diagnostics">{{cite web \| url = http://www.criticaldiagnostics.com/news-FDA-Approval-2011.html \| title = Critical Diagnostics \| date = \| work = \| publisher = Critical Diagnostics \| accessdate = }}</ref> The assay has [[Food and Drug Administration]] approval and a [[CE Mark]].<ref name="url510(k) Premarket Notification">{{cite web \| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=36927 \| title = 510(k) Premarket Notification \| date = \| work = \| publisher = United States Food and Drug Administration \| accessdate = }}</ref>		ST2 is measured by an [[immunoassay]], commercially marketed as the Presage ST2 Assay by Critical Diagnostics of San Diego, California.<ref name="urlCritical Diagnostics">{{cite web \| url = http://www.criticaldiagnostics.com/news-FDA-Approval-2011.html \| title = Critical Diagnostics \| date = \| work = \| publisher = Critical Diagnostics \| accessdate = }}</ref>

			The assay has [[Food and Drug Administration]] approval and a [[CE Mark]].<ref name="url510(k) Premarket Notification">{{cite web \| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=36927 \| title = 510(k) Premarket Notification \| date = \| work = \| publisher = United States Food and Drug Administration \| accessdate = }}</ref>

			== '''The ST2/IL-33 Axis in Immune Cells''' '''in Inflammatory Disease''' ==
			* '''Il1rl1 (also known as ST2)''' is a member of the IL-1 superfamily, and its ligand IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a decoy receptor, sequesters free IL-33, and does not signal, and a membrane-bound form (ST2), that activates the MyD88/NF-κB signaling pathway to enhance mast cell, Th2, regulatory T cell (Treg), and innate lymphoid cell type 2 functions.<ref>''Griesenauer B and Paczesny S (2017) The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front. Immunol. 8:475. doi: 10.3389/fimmu.2017.00475''</ref>
			* '''sST2 levels''' are increased in patients with inflammatory bowel disease, acute cardiac and small bowel transplant allograft rejection, colon and gastric cancers, gut mucosal damage during viral infection, pulmonary disease, heart disease, and graft-versus-host disease.
			* Recently, sST2 has been shown to be secreted by '''intestinal pro-inflammatory T cells''' during gut inflammation. <ref>''Griesenauer B and Paczesny S (2017) The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front. Immunol. 8:475. doi: 10.3389/fimmu.2017.00475''</ref>

	==References==		==References==

Sandbox:AR

Anum Ijaz — Thu, 12 Nov 2026 15:09:00 GMT

← Older revision		Revision as of 15:09, 12 November 2026
Line 16:		Line 16:

	'''Recommended indications (R2):'''		'''Recommended indications (R2):'''
	* Somatotrophinoma or prolactinoma diagnosed at or before 18 years of age.		* Somatotrophinoma or [[prolactinoma]] diagnosed at or before 18 years of age.
	* A personal history of pituitary adenoma and a blood relative with a pituitary adenoma.		* A personal history of pituitary adenoma and a blood relative with a pituitary adenoma.
	* A personal or family history of non-pituitary tumors associated with an established pituitary tumor predisposition gene.		* A personal or family history of non-pituitary tumors associated with an established pituitary tumor predisposition gene.

Lower gastrointestinal bleeding medical therapy

Dr Muhammad Saad — Thu, 12 Nov 2026 13:04:49 GMT

Show changes

User:Dr Muhammad Saad

Dr Muhammad Saad — Wed, 11 Nov 2026 08:34:44 GMT

← Older revision		Revision as of 08:34, 11 November 2026
Line 6:		Line 6:

	==Current Position==		==Current Position==
	* Scholar/Editor ~~and Mentor~~ at '''WikiDoc.org'''		* Scholar/Editor at '''WikiDoc.org'''
	I create original content on my areas of interest and refresh older chapters to keep the medical information current.		I create original content on my areas of interest and refresh older chapters to keep the medical information current.

Line 21:		Line 21:
	==Clinical Experience==		==Clinical Experience==

	* '''Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan (01/~~2026~~ - Current)'''		* '''Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan (03/2025 - Current)'''

	'''Position:''' Resident Physician		'''Position:''' Resident Physician
Line 27:		Line 27:
	'''Supervisor Attending:''' Dr. Moona Humaira, MBBS, FCPS		'''Supervisor Attending:''' Dr. Moona Humaira, MBBS, FCPS

	* '''~~inova loudoun hospital~~ (07/2026 - 07/~~2022~~)'''		* '''Abington Memorial Hospital, PA (08/2026 - 08/2026)'''

	'''Position:''' Medical Observer		'''Position:''' Medical Observer

	'''Supervisor Attending:''' Dr. ~~Rauf Chaudhry~~, MD.		'''Supervisor Attending:''' Dr. Sunil Nair, MD.

	*'''~~Brown University Health~~ (06/2026 - 06/~~2022~~)'''		*'''Baylor Scott and White Medical Centre, Grapevine, TX (07/2026 - 08/2026)'''

	'''Position:''' Medical Observer		'''Position:''' Medical Observer

	'''Supervisor Attending:''' Dr. ~~Farukhuddin~~ MD.		'''Supervisor Attending:''' Dr. Arshad A Quddoos MD.

	* '''~~Liaquat University Civil Hospital~~, ~~Hyderabad/Jamshoro Pakistan~~ (05/~~2023~~ - 12/~~2025~~)'''		* '''Norman Endocrinology Associates, Norman, OK(06/2026 - 07/2026)'''

	'''Position:''' Medical ~~Officer with Dept. of Neurology and General Medicine~~		'''Position:''' Medical Observer

	~~'''Supervisor Attending:''' Prof. Dr. Manzoor Ali Lakhair, MBBS, FCPS.; Dr. Muhammad Aslam Rind, MBBS, FCPS, FRCP.~~

	* '''Carondelet St. Joseph’s Hospital, Tucson, AZ (06/2025 - 06/2025)'''

	~~'''Position:'''~~ Observer

	~~'''Supervisor Attending:''' Dr. Fahad J. Laghari, MD.~~

	* '''~~Charleston Area Medical Center, Charleston, WV (05/2025 - 05/2025)~~'''		'''Supervisor Attending:''' Dr. Lubna Mirza, MD.

	'''~~Position:~~''' ~~Observer~~		* '''Hashim Medical City Hospital, Hyderabad, Pakistan(09/2024 - 02/2025)'''

	'''~~Supervisor Attending~~:''' ~~Dr. Suzanne Crandall, DO, AOA.~~		'''Position:''' Medical Officer in Gastroenterology department

	* '''~~Boston Medical Center-South, Brockton, MA (04/2025 - 04/2025)~~'''		'''Supervisor Attending:''' Dr. Ai Akbar Siddiqui, FCPS

	'''~~Position:~~''' ~~Observer~~		* '''Liaquat University Civil Hospital, Hyderabad/Jamshoro Pakistan (05/2023 - 05/2024)'''

	'''~~Supervisor Attending~~:''' ~~Dr. Terri Spenser, MD.~~		'''Position:''' House Officer

Sandbox:AR

Amna Riaz — Wed, 11 Nov 2026 02:48:31 GMT

Show changes

Cell-cycle box gene transcriptions

Marshallsumter — Tue, 10 Nov 2026 08:43:42 GMT

CCB variant samplings

← Older revision		Revision as of 08:43, 10 November 2026
Line 78:		Line 78:
	==CCB variant samplings==		==CCB variant samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[Cell-cycle box gene transcriptions#CCB variant samplings\|CCB variant samplings]]

	Copying a responsive elements consensus sequence CACGAAA, ACGAAA and C-CGAAA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs. Actual consensus sequences to conform should contain CACGAAA, ACGAAA or CCGAAA.		Copying a responsive elements consensus sequence CACGAAA, ACGAAA and C-CGAAA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs. Actual consensus sequences to conform should contain CACGAAA, ACGAAA or CCGAAA.

File:Abid Qurrat-Ul-Ain circle.png

Gerald Chi — Mon, 09 Nov 2026 06:19:42 GMT

Gerald Chi deleted page File:Abid Qurrat-Ul-Ain circle.png User request

Back pain differential diagnosis

Elizabeth Nguyen — Sun, 08 Nov 2026 06:49:07 GMT

Show changes

Back pain causes

Elizabeth Nguyen — Sun, 08 Nov 2026 05:42:00 GMT

Show changes

Back pain epidemiology and demographics

Elizabeth Nguyen — Sun, 08 Nov 2026 04:50:19 GMT

Show changes

User:Julinka Auta Fernandes

Julinka Auta Fernandes — Fri, 06 Nov 2026 23:47:28 GMT

WikiDoc Contributions

@@ Line 17: / Line 17: @@
 '''WikiDoc Scholar and medical content contributor — 2026–present'''
-The linked portfolio below contains '''63 clinical microchapter and patient-information pages'''. These entries describe contribution areas within WikiDoc's collaborative editorial work.
+Contributes to clinical microchapters on multiple sclerosis, transverse myelitis, neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis. Her work includes literature searching, synthesis of published guidelines and consensus statements, citation checking, medical writing, and revision of MediaWiki content.
 <div style="background:#f8fafc; border:1px solid #e0e7ed; padding:10px 14px; margin:12px 0 18px;">
@@ Line 102: / Line 101: @@
 | style="vertical-align:top; padding:10px 12px;" | [[Neuromyelitis optica spectrum disorder|NMOSD main page]] &middot; [[Neuromyelitis optica spectrum disorder (patient information)|Patient information]]
 |}
+{| class="wikitable mw-collapsible mw-collapsed" style="width:100%; margin:0 0 16px; border:1px solid #d5e0e8; border-collapse:collapse;"
 == Certifications and Professional Development ==

ST2 cardiac biomarker

Gromeromd — Fri, 06 Nov 2026 20:08:46 GMT

← Older revision		Revision as of 20:08, 6 November 2026
Line 20:		Line 20:
	}}		}}

	The '''ST2 cardiac biomarker''' is a protein [[biomarker (medicine)\|biomarker]] of [[Cardiac muscle\|cardiac]] stress encoded by the '''[[IL1RL1]]''' gene. ST2 signals the presence and severity of adverse cardiac remodeling and tissue [[fibrosis]], which occurs in response to [[myocardial infarction]], [[acute coronary syndrome]], or worsening [[heart failure]].<ref name="pmid20425491">{{cite journal \|vauthors=Shah RV, Januzzi JL \| title = ST2: a novel remodeling biomarker in acute and chronic heart failure \| journal = Curr Heart Fail Rep \| volume = 7 \| issue = 1 \| pages = 9–14 \|date=March 2010 \| pmid = 20425491 \| doi = 10.1007/s11897-010-0005-9 }}</ref><ref name="pmid19017513">{{cite journal \|vauthors=Rehman SU, Mueller T, Januzzi JL \| title = Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure \| journal = J. Am. Coll. Cardiol. \| volume = 52 \| issue = 18 \| pages = 1458–65 \|date=October 2008 \| pmid = 19017513 \| doi = 10.1016/j.jacc.2008.07.042 }}</ref>		The '''ST2 cardiac biomarker''' is a protein [[biomarker (medicine)\|biomarker]] of [[Cardiac muscle\|cardiac]] stress encoded by the '''[[IL1RL1]]''' gene. ST2 signals the presence and severity of adverse cardiac remodeling and tissue [[fibrosis]], which occurs in response to [[myocardial infarction]], [[acute coronary syndrome]], or worsening [[heart failure]].<ref name="pmid20425491">{{cite journal \|vauthors=Shah RV, Januzzi JL \| title = ST2: a novel remodeling biomarker in acute and chronic heart failure \| journal = Curr Heart Fail Rep \| volume = 7 \| issue = 1 \| pages = 9–14 \|date=March 2010 \| pmid = 20425491 \| doi = 10.1007/s11897-010-0005-9 }}</ref><ref name="pmid19017513">{{cite journal \|vauthors=Rehman SU, Mueller T, Januzzi JL \| title = Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure \| journal = J. Am. Coll. Cardiol. \| volume = 52 \| issue = 18 \| pages = 1458–65 \|date=October 2008 \| pmid = 19017513 \| doi = 10.1016/j.jacc.2008.07.042 }}</ref>

	ST2 provides prognostic information that is independent of other cardiac biomarkers such as [[Brain natriuretic peptide\|BNP]], [[NT-proBNP]], highly sensitive [[troponin]], GDF-15, and [[galectin-3]].<ref name="doi=10.1016/j.jchf.2012.10.002">doi=10.1016/j.jchf.2012.10.002</ref> One study indicated that discrimination is independent of age, [[body mass index]], history of heart failure, [[anemia]] and impaired [[renal failure]] or sex.<ref>{{cite web \|url=http://www.criticaldiagnostics.com/OUS/news/news-072415.html \|title=MULTIPLE STUDIES SHOW SUPERIORITY OF CRITICAL DIAGNOSTICS’ ST2 OVER BNP, NT-PROBNP AND OTHER HEART FAILURE BIOMARKERS. \|accessdate=October 27, 2016 \|date=July 24, 2015}}</ref>		ST2 provides prognostic information that is independent of other cardiac biomarkers such as [[Brain natriuretic peptide\|BNP]], [[NT-proBNP]], highly sensitive [[troponin]], GDF-15, and [[galectin-3]].<ref name="doi=10.1016/j.jchf.2012.10.002">doi=10.1016/j.jchf.2012.10.002</ref> One study indicated that discrimination is independent of age, [[body mass index]], history of heart failure, [[anemia]] and impaired [[renal failure]] or sex.<ref>{{cite web \|url=http://www.criticaldiagnostics.com/OUS/news/news-072415.html \|title=MULTIPLE STUDIES SHOW SUPERIORITY OF CRITICAL DIAGNOSTICS’ ST2 OVER BNP, NT-PROBNP AND OTHER HEART FAILURE BIOMARKERS. \|accessdate=October 27, 2016 \|date=July 24, 2015}}</ref>

	== Protein ==		== Protein ==
	{{main article\|IL1RL1}}		{{main article\|IL1RL1}}
	ST2 is a member of the interleukin 1 receptor family. The ST2 protein has two isoforms and is directly implicated in the progression of cardiac disease: a soluble form (referred to as soluble ST2 or sST2) and a membrane-bound receptor form (referred to as the ST2 receptor or ST2L). When the myocardium is stretched, the ST2 gene is upregulated, increasing the concentration of circulating soluble ST2.<ref name="doi=10.1016/j.jchf.2012.10.002"/> The ligand for ST2 is the cytokine Interleukin-33(IL-33). Binding of IL-33 to the ST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counterbalanced by the level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of soluble ST2.		ST2 is a member of the interleukin 1 receptor family. The ST2 protein has two isoforms and is directly implicated in the progression of cardiac disease: a soluble form (referred to as soluble ST2 or sST2) and a membrane-bound receptor form (referred to as the ST2 receptor or ST2L). When the myocardium is stretched, the ST2 gene is upregulated, increasing the concentration of circulating soluble ST2.<ref name="doi=10.1016/j.jchf.2012.10.002"/> The ligand for ST2 is the cytokine Interleukin-33(IL-33). Binding of IL-33 to the ST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counterbalanced by the level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of soluble ST2.

	== Correlation with mortality ==		== Correlation with mortality ==

	Published and peer-reviewed findings indicate that ST2 is a predictor of [[death\|mortality]] at presentation.<ref name="pmid18480207">{{cite journal \| author = Braunwald E \| title = Biomarkers in heart failure \| journal = N. Engl. J. Med. \| volume = 358 \| issue = 20 \| pages = 2148–59 \|date=May 2008 \| pmid = 18480207 \| doi = 10.1056/NEJMra0800239 }}</ref> Studies have shown patients with ST2 levels above a clinical threshold consistently have a much higher risk of mortality while, equally important, patients with ST2 levels below threshold have a very low risk of mortality.<ref name="pmid21178018">{{cite journal \|vauthors=Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP \| title = High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure \| journal = Circ Heart Fail \| volume = 4 \| issue = 2 \| pages = 180–7 \|date=March 2011 \| pmid = 21178018 \| pmc = 3163169 \| doi = 10.1161/CIRCHEARTFAILURE.110.958223 }}</ref><ref name="pmid22096031">{{cite journal \|vauthors=Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA \| title = Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| journal = Clin. Chem. \| volume = 58\| issue = 1\| pages = 257–66\|date=November 2011 \| pmid = 22096031 \| doi = 10.1373/clinchem.2011.173369 \| pmc = 4277435}}</ref> Although it has been shown that ST2 concentrations correlate with heart failure severity<ref name="pmid20804518">{{cite journal \|vauthors=Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C \| title = Interleukin family member ST2 and mortality in acute dyspnoea \| journal = J. Intern. Med. \| volume = 268 \| issue = 5 \| pages = 493–500 \|date=November 2010 \| pmid = 20804518 \| doi = 10.1111/j.1365-2796.2010.02263.x }}</ref> there is no level that perfectly separates patients with and without heart failure for disease diagnosis. However, as a prognostic marker it has been clearly shown that patients are at a higher risk of adverse outcomes when ST2 levels are above a cutoff value of 35 ng/mL.<ref name="pmid21178018"/>		Published and peer-reviewed findings indicate that ST2 is a predictor of [[death\|mortality]] at presentation.<ref name="pmid18480207">{{cite journal \| author = Braunwald E \| title = Biomarkers in heart failure \| journal = N. Engl. J. Med. \| volume = 358 \| issue = 20 \| pages = 2148–59 \|date=May 2008 \| pmid = 18480207 \| doi = 10.1056/NEJMra0800239 }}</ref> Studies have shown patients with ST2 levels above a clinical threshold consistently have a much higher risk of mortality while, equally important, patients with ST2 levels below threshold have a very low risk of mortality.<ref name="pmid21178018">{{cite journal \|vauthors=Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP \| title = High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure \| journal = Circ Heart Fail \| volume = 4 \| issue = 2 \| pages = 180–7 \|date=March 2011 \| pmid = 21178018 \| pmc = 3163169 \| doi = 10.1161/CIRCHEARTFAILURE.110.958223 }}</ref><ref name="pmid22096031">{{cite journal \|vauthors=Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA \| title = Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| journal = Clin. Chem. \| volume = 58\| issue = 1\| pages = 257–66\|date=November 2011 \| pmid = 22096031 \| doi = 10.1373/clinchem.2011.173369 \| pmc = 4277435}}</ref> Although it has been shown that ST2 concentrations correlate with heart failure severity<ref name="pmid20804518">{{cite journal \|vauthors=Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C \| title = Interleukin family member ST2 and mortality in acute dyspnoea \| journal = J. Intern. Med. \| volume = 268 \| issue = 5 \| pages = 493–500 \|date=November 2010 \| pmid = 20804518 \| doi = 10.1111/j.1365-2796.2010.02263.x }}</ref> there is no level that perfectly separates patients with and without heart failure for disease diagnosis. However, as a prognostic marker it has been clearly shown that patients are at a higher risk of adverse outcomes when ST2 levels are above a cutoff value of 35 ng/mL.<ref name="pmid21178018"/>

	==Patients with ACS==		==Patients with ACS==

	ST2 is a strong predictor of cardiovascular death and risk of developing new heart failure in [[STEMI\|ST Elevation Myocardial Infarction]] (STEMI) & [[Acute coronary syndrome\|NSTE-ACS]] patients. In patients presenting with [[Acute coronary syndrome\|Acute Coronary Syndrome]] (ACS), those in the highest quartile (above 35 ng/ml) have more than 3 times higher risk of cardiovascular death and new heart failure at 30 days, than those in the lower quartiles. At one year, there is a [[relative risk]] of 2.3 for adverse outcomes.<ref name="urlClinical Chemistry Role of ST2 in Non-ST">{{cite web \| url = http://www.clinchem.org/content/58/1/257.abstract \| title = Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| author = P Kohli \| date = \| work = \| publisher = Clinical Chemistry \| accessdate = }}</ref>		ST2 is a strong predictor of cardiovascular death and risk of developing new heart failure in [[STEMI\|ST Elevation Myocardial Infarction]] (STEMI) & [[Acute coronary syndrome\|NSTE-ACS]] patients. In patients presenting with [[Acute coronary syndrome\|Acute Coronary Syndrome]] (ACS), those in the highest quartile (above 35 ng/ml) have more than 3 times higher risk of cardiovascular death and new heart failure at 30 days, than those in the lower quartiles. At one year, there is a [[relative risk]] of 2.3 for adverse outcomes.<ref name="urlClinical Chemistry Role of ST2 in Non-ST">{{cite web \| url = http://www.clinchem.org/content/58/1/257.abstract \| title = Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial \| author = P Kohli \| date = \| work = \| publisher = Clinical Chemistry \| accessdate = }}</ref>

	ST2 is an active participant in the cardiac [[Ventricular remodeling\|remodeling]] pathway and could identify which patients will respond to [[Eplerenone]], or other therapies that reverse myocardial [[fibrosis]].<ref name="pmid20117403">{{cite journal \|vauthors=Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ \| title = Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction \| journal = J Am Coll Cardiol \| volume = 55 \| issue = 3 \| pages = 243–50 \|date=January 2010 \| pmid = 20117403 \| doi = 10.1016/j.jacc.2009.08.047}}</ref>		ST2 is an active participant in the cardiac [[Ventricular remodeling\|remodeling]] pathway and could identify which patients will respond to [[Eplerenone]], or other therapies that reverse myocardial [[fibrosis]].<ref name="pmid20117403">{{cite journal \|vauthors=Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ \| title = Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction \| journal = J Am Coll Cardiol \| volume = 55 \| issue = 3 \| pages = 243–50 \|date=January 2010 \| pmid = 20117403 \| doi = 10.1016/j.jacc.2009.08.047}}</ref>
Line 46:		Line 46:

	== The ST2 test ==		== The ST2 test ==
	ST2 is measured by an [[immunoassay]], commercially marketed as the Presage ST2 Assay by Critical Diagnostics of San Diego, California.<ref name="urlCritical Diagnostics">{{cite web \| url = http://www.criticaldiagnostics.com/news-FDA-Approval-2011.html \| title = Critical Diagnostics \| date = \| work = \| publisher = Critical Diagnostics \| accessdate = }}</ref> The assay has [[Food and Drug Administration]] approval and a [[CE Mark]].<ref name="url510(k) Premarket Notification">{{cite web \| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=36927 \| title = 510(k) Premarket Notification \| date = \| work = \| publisher = United States Food and Drug Administration \| accessdate = }}</ref>		ST2 is measured by an [[immunoassay]], commercially marketed as the Presage ST2 Assay by Critical Diagnostics of San Diego, California.<ref name="urlCritical Diagnostics">{{cite web \| url = http://www.criticaldiagnostics.com/news-FDA-Approval-2011.html \| title = Critical Diagnostics \| date = \| work = \| publisher = Critical Diagnostics \| accessdate = }}</ref> The assay has [[Food and Drug Administration]] approval and a [[CE Mark]].<ref name="url510(k) Premarket Notification">{{cite web \| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=36927 \| title = 510(k) Premarket Notification \| date = \| work = \| publisher = United States Food and Drug Administration \| accessdate = }}</ref>

	==References==		==References==

Autoimmune Encephalitis

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:34:47 GMT

← Older revision		Revision as of 12:34, 6 November 2026
Line 34:		Line 34:

	== Treatment ==		== Treatment ==
	[[Autoimmune Encephalitis medical therapy\|Medical Therapy]] \| [[Autoimmune Encephalitis ~~Interventions~~\|Interventios]] \| [[Autoimmune Encephalitis ~~Surgery~~\|Surgery]] \| [[Autoimmune Encephalitis primary prevention\|Primary Prevention]] \| [[Autoimmune Encephalitis secondary prevention\|Secondary Prevention]] \| [[Autoimmune Encephalitis cost-effectiveness of therapy\|Cost-Effectiveness of Therapy]] \| [[Autoimmune Encephalitis future or investigational therapies\|Future or Investigational Therapies]]		[[Autoimmune Encephalitis medical therapy\|Medical Therapy]] \| [[Autoimmune Encephalitis interventions\|Interventios]] \| [[Autoimmune Encephalitis surgery\|Surgery]] \| [[Autoimmune Encephalitis primary prevention\|Primary Prevention]] \| [[Autoimmune Encephalitis secondary prevention\|Secondary Prevention]] \| [[Autoimmune Encephalitis cost-effectiveness of therapy\|Cost-Effectiveness of Therapy]] \| [[Autoimmune Encephalitis future or investigational therapies\|Future or Investigational Therapies]]

	== Case Studies ==		== Case Studies ==

Autoimmune Encephalitis future or investigational therapies

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:32:09 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis research is evaluating targeted immune treatments for patients with incomplete response to conventional therapy. Investigational treatment should be distinguished from established first- and second-line approaches. Published recommendations support specialist reassessment before rescue treatment because persistent disability does not necessarily..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] research is evaluating targeted immune treatments for patients with incomplete response to conventional therapy. Investigational treatment should be distinguished from established first- and second-line approaches. Published recommendations support specialist reassessment before rescue treatment because persistent disability does not necessarily represent ongoing immune activity.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.</ref>

==Future or Investigational Therapies==
===B-Cell-Directed Treatment===
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies is being studied in the ExTINGUISH trial of inebilizumab, which targets cluster of differentiation 19 (CD19)-expressing B-lineage cells. The published phase 2b randomized, placebo-controlled protocol evaluates treatment in addition to first-line care and includes clinical, cognitive, quality-of-life, and biomarker outcomes. A protocol describes planned methods rather than proving efficacy.<ref name="ExTINGUISH2025">[https://pubmed.ncbi.nlm.nih.gov/40625668/ A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial]. ''Neurol Open Access''. 2025;1(2):e000007. doi:10.1212/WN9.0000000000000007. PMID:40625668. Trial registration: [https://clinicaltrials.gov/study/NCT04372615 NCT04372615].</ref>

===Interleukin-6 Receptor Blockade===
Autoimmune encephalitis research includes satralizumab, an interleukin-6 (IL-6) receptor inhibitor. The phase 3 CIELO study evaluates it in NMDAR antibody encephalitis and leucine-rich glioma-inactivated protein 1 (LGI1) antibody encephalitis. The sponsor's study summary describes randomized comparison with placebo and functional and safety outcomes.<ref name="CIELO">Genentech. [https://www.genentech-medinfo.com/pipeline-and-clinical-trials/neurology/satralizumab/cielo.html Phase III: Satralizumab in NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis (Cielo)]. Trial registration: [https://clinicaltrials.gov/study/NCT05503264 NCT05503264]. Accessed November 6, 2026.</ref>

Autoimmune encephalitis refractory to conventional treatment has also been treated with tocilizumab, another IL-6 receptor inhibitor. Supporting evidence has largely involved observational experience; it is not a routine first-line treatment.<ref name="Abboud2021" />

===Plasma-Cell-Directed Treatment===
Autoimmune encephalitis research includes bortezomib, a proteasome inhibitor targeting antibody-producing plasma cells. GENERATE-BOOST is a randomized, placebo-controlled phase 2 trial in severe disease. Trial registration should not be interpreted as evidence of benefit.<ref name="GENERATEBOOST">ClinicalTrials.gov. [https://clinicaltrials.gov/study/NCT03993262 Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (Generate-Boost)]. NCT03993262. See also [https://drks.de/search/en/trial/DRKS00017497 German Clinical Trials Register: DRKS00017497]. Accessed November 6, 2026.</ref>

Autoimmune encephalitis is also being investigated with combined B-cell and plasma-cell targeting. The 2026 RADIA protocol compares ofatumumab, targeting cluster of differentiation 20 (CD20), followed by daratumumab, targeting cluster of differentiation 38 (CD38), with comparator regimens. Planned outcomes include disability, cognition, hospitalization, and safety. This publication is a trial protocol, not an efficacy report.<ref name="RADIA2026">Xie W, Zhang LJ, Yue C, et al. [https://pubmed.ncbi.nlm.nih.gov/42293080/ Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial]. ''Front Neurol''. 2026;17:1783651. doi:10.3389/fneur.2026.1783651. PMID:42293080. Trial registration: [https://clinicaltrials.gov/study/NCT06867991 NCT06867991].</ref>

===Neonatal Fc Receptor Antagonism===
Autoimmune encephalitis studies are evaluating efgartigimod, which blocks the neonatal Fc receptor (FcRn) and reduces recycling of immunoglobulin G (IgG). A small 2026 retrospective cohort of 15 patients reported improvement associated with treatment. Without a control group, it cannot establish causation or comparative effectiveness.<ref name="Efgartigimod2026">[https://pubmed.ncbi.nlm.nih.gov/42159021/ The Clinical Efficacy and Safety of Efgartigimod in the Treatment of Autoimmune Encephalitis]. ''Immunol Invest''. 2026. PMID:42159021.</ref>

==Interpretation and Safety==
Autoimmune encephalitis investigational evidence must be interpreted according to study design. Uncontrolled improvement may reflect concurrent immunotherapy, natural recovery, or selection bias. Small cohorts cannot reliably exclude uncommon or delayed adverse effects.<ref name="Efgartigimod2026" />

Autoimmune encephalitis rescue treatment requires review of diagnosis, previous treatment adequacy, infection, and associated neoplasm. Additional immunosuppression carries treatment-specific risks and should be managed through experienced specialist teams.<ref name="Abboud2021" />

==Future Research Priorities==
Autoimmune encephalitis trials should evaluate cognition, quality of life, and meaningful functional recovery alongside global disability. ExTINGUISH incorporates these outcomes and biofluid studies to investigate treatment response and disease biology.<ref name="ExTINGUISH2025" /> Important unanswered questions include which subtypes benefit, optimal timing, treatment duration, relapse prevention, and long-term safety.

==Clinical Trial Information==
Autoimmune encephalitis trial eligibility and recruitment status change over time and may differ by country or site. Consult the linked registry records and treating specialist for current information. This chapter summarizes research available on November 6, 2026; listed therapies should not be treated as interchangeable or automatically appropriate for an individual patient.

==Related Chapters==
* [[Autoimmune Encephalitis medical therapy|Medical therapy]].
* [[Autoimmune Encephalitis pediatric treatment considerations|Pediatric treatment considerations]].
* [[Autoimmune Encephalitis secondary prevention|Secondary prevention]].
* [[Autoimmune Encephalitis rehabilitation|Rehabilitation]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis cost-effectiveness of therapy

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:28:06 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis can impose substantial hospital and long-term care costs. Published economic evidence includes resource-use studies and diagnostic-screening models, but these do not establish a universally most cost-effective immunotherapy.<ref name="Keller2026">Keller N, Bertram D, Hamer H, et al. [https://pubmed.ncbi.nlm.nih.gov/41998723/ Hospital resource use..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] can impose substantial hospital and long-term care costs. Published economic evidence includes resource-use studies and diagnostic-screening models, but these do not establish a universally most cost-effective immunotherapy.<ref name="Keller2026">Keller N, Bertram D, Hamer H, et al. [https://pubmed.ncbi.nlm.nih.gov/41998723/ Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study]. ''Neurol Res Pract''. 2026;8(1):26. doi:10.1186/s42466-026-00491-7. PMID:41998723.</ref><ref name="Ross2020">Ross EL, Becker JE, Linnoila JJ, Soeteman DI. [https://pubmed.ncbi.nlm.nih.gov/33211912/ Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States]. ''J Clin Psychiatry''. 2020;82(1):19m13168. doi:10.4088/JCP.19m13168. PMID:33211912.</ref>

==Cost-Effectiveness of Therapy==
===Interpretation of Economic Evidence===
Autoimmune encephalitis cost-effectiveness assessments must compare both costs and health outcomes between strategies. A treatment with a lower purchase price is not necessarily better value if it leads to more complications, disability, or hospital care. Hospital-cost studies alone cannot establish an incremental cost-effectiveness ratio (ICER), which compares additional cost with additional health benefit. Quality-adjusted life-years (QALYs) combine survival and health-related quality of life.<ref name="Ross2020" />

===Hospital Resource Use===
Autoimmune encephalitis resource use was evaluated in a 2026 German single-center retrospective cohort of 35 patients. Median direct hospital costs during the first year were €26,547 per patient. Patients admitted to an intensive care unit (ICU) had higher costs than those not admitted: €69,822 versus €20,234. Hospital duration, particularly ICU stay, was a major cost driver.<ref name="Keller2026" />

Autoimmune encephalitis cost figures from this study reflect its setting, costing method, and case mix. They are not current treatment quotations, patient bills, or estimates for other countries. The study did not compare the cost per QALY of competing immunotherapies.<ref name="Keller2026" />

===Treatment Selection===
Autoimmune encephalitis guidelines base therapy on diagnostic confidence, severity, antibody subtype, contraindications, and response. High-dose corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, and selected second-line treatments have different delivery and monitoring requirements. The Canadian consensus does not establish a formal economic ranking of these options.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

Autoimmune encephalitis treatment costs should therefore be considered together with clinical suitability, access, administration, adverse effects, and continuing care. Available evidence does not justify declaring rituximab, cyclophosphamide, IVIG, or plasma exchange the most cost-effective treatment for every patient.<ref name="Hahn2024" /><ref name="Keller2026" />

===Timely Diagnosis and Coordinated Care===
Autoimmune encephalitis care pathways may improve efficiency. A 2024 pediatric single-center study found shorter time to diagnostic evaluation and treatment after pathway implementation. It did not demonstrate a statistically significant reduction in hospital stay or provide a formal cost-effectiveness analysis.<ref name="Barter2024">Barter KM, Fuchs C, Graham TB, Pagano LM, Vater M. [https://pubmed.ncbi.nlm.nih.gov/38173540/ Anti-NMDAR Encephalitis Clinical Practice Guideline: Improving Time to Diagnosis, Treatment, and Hospital Length of Stay]. ''Neurol Clin Pract''. 2024;14(1):e200218. doi:10.1212/CPJ.0000000000200218. PMID:38173540.</ref>

Autoimmune encephalitis guidelines recommend timely appropriate treatment for clinical benefit. Potential economic benefits should not be represented as proven savings without a comparative economic evaluation.<ref name="Hahn2024" /><ref name="Barter2024" />

==Related Economic Evidence: Diagnostic Screening==
Autoimmune encephalitis screening was assessed in a United States decision model comparing routine serum antibody screening with clinically targeted testing in first-episode psychosis. Over five years, estimated ICERs were US$99,330 per QALY from a societal perspective and US$147,460 per QALY from a healthcare-sector perspective. Model costs used 2015 United States dollars.<ref name="Ross2020" />

Autoimmune encephalitis screening results depended strongly on assumptions, including immunotherapy effectiveness. This was a diagnostic-strategy model, not a head-to-head comparison of treatment regimens, and it does not independently establish a clinical recommendation for universal antibody screening.<ref name="Ross2020" />

==Evidence Limitations==
Autoimmune encephalitis economic conclusions are limited by small cohorts, heterogeneous disease severity, local prices, different costing perspectives, and incomplete measurement of long-term disability and caregiver burden. Economic findings should not be transferred between healthcare systems without reassessment.<ref name="Keller2026" /><ref name="Ross2020" />

==Related Chapters==
* [[Autoimmune Encephalitis medical therapy|Medical therapy]].
* [[Autoimmune Encephalitis interventions|Interventions]].
* [[Autoimmune Encephalitis rehabilitation|Rehabilitation]].
* [[Autoimmune Encephalitis screening|Screening]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis secondary prevention

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:17:41 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis secondary prevention focuses on reducing relapse risk and recognizing recurrent disease after an initial episode. Follow-up and preventive treatment should reflect disease subtype, previous attacks, severity, and treatment risks. Long-term immunosuppression is not routinely recommended for every patient after a first presentation.<ref name="Hahn2..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] secondary prevention focuses on reducing relapse risk and recognizing recurrent disease after an initial episode. Follow-up and preventive treatment should reflect disease subtype, previous attacks, severity, and treatment risks. Long-term immunosuppression is not routinely recommended for every patient after a first presentation.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

==Secondary Prevention==
===Treatment Continuity After the Acute Episode===
Autoimmune encephalitis may require bridging treatment and gradual withdrawal of corticosteroids after acute therapy. The approach depends on response, adverse effects, and anticipated relapse risk; abrupt discontinuation of prescribed immunotherapy should be avoided without a clinician-directed plan.<ref name="Abboud2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

===Maintenance Immunotherapy===
Autoimmune encephalitis with confirmed relapses may justify maintenance immunotherapy. Selected options include rituximab, mycophenolate mofetil, or azathioprine. Drug selection and duration require specialist review of antibody subtype, attack severity, comorbidities, and tolerability. Proposed maintenance periods are empirical; a universal fixed duration is not established.<ref name="Abboud2021" />

Autoimmune encephalitis with persistent residual symptoms should not automatically be interpreted as active inflammation requiring additional immunosuppression. Confirm the diagnosis and assess objective evidence before escalating treatment.<ref name="Hahn2024" />

===Recognizing Suspected Relapse===
Autoimmune encephalitis relapse may reproduce earlier symptoms or present differently. New cognitive, behavioral, seizure, movement, or functional deterioration warrants reassessment. Evaluate infection, medication effects, metabolic disturbance, and seizures as alternative explanations. Antibody titers correlate imperfectly with disease activity and should not independently determine relapse or treatment escalation.<ref name="Hahn2024" />

Autoimmune encephalitis follow-up should include a plan for patients and caregivers to report changes and obtain timely neurological review. Persistent deficits also require rehabilitation and symptom-directed care.<ref name="Abboud2021" />

===Associated Neoplasm Surveillance===
Autoimmune encephalitis may require repeat tumor investigation after a negative initial screen or at relapse. Surveillance depends on the neuronal antibody, phenotype, age, cancer risk, and previous findings; repeated whole-body imaging is not required for every patient.<ref name="Hahn2024" />

For risk-specific schedules, see [[Autoimmune Encephalitis screening for an associated neoplasm|screening for an associated neoplasm]]. Tumor treatment is discussed under [[Autoimmune Encephalitis surgery|surgery]].

===Pediatric Considerations===
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies in children usually does not require maintenance immunosuppression beyond six months, except with severe, prolonged, or relapsing disease. International consensus recommends considering more prolonged treatment after relapse. These recommendations are specific to pediatric NMDAR antibody encephalitis and should not automatically be extended to other subtypes.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

==Treatment Safety==
Autoimmune encephalitis prevention plans must balance relapse risk against immunotherapy toxicity. For rituximab, screen for hepatitis B infection, review vaccinations, and obtain baseline blood counts; previous hepatitis B infection requires specialist assessment of reactivation prevention. Monitor for infusion reactions and serious infections.<ref name="RituximabLabel">Genentech. [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563 Rituxan (rituximab): prescribing information]. DailyMed, United States National Library of Medicine.</ref>

Autoimmune encephalitis patients receiving prolonged corticosteroids or combined immunosuppression may need infection prophylaxis and bone protection according to their regimen and individual risk.<ref name="Abboud2021" /><ref name="Nosadini2021" /> These measures prevent treatment complications rather than directly preventing autoimmune relapse.

==Related Chapters==
* [[Autoimmune Encephalitis primary prevention|Primary prevention]].
* [[Autoimmune Encephalitis medical therapy|Medical therapy]].
* [[Autoimmune Encephalitis pediatric treatment considerations|Pediatric treatment considerations]].
* [[Autoimmune Encephalitis rehabilitation|Rehabilitation]].
* [[Autoimmune Encephalitis symptomatic and supportive therapy|Symptomatic and supportive therapy]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis primary prevention

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:12:18 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no established disease-specific strategy that reliably prevents a first episode. Primary prevention concerns preventing disease before it develops; treatment of established encephalitis and prevention of relapse are separate issues. Expert information from Mayo Clinic emphasizes that consistent preventive measures for autoimmune causes of enc..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] has no established disease-specific strategy that reliably prevents a first episode. Primary prevention concerns preventing disease before it develops; treatment of established encephalitis and prevention of relapse are separate issues. Expert information from Mayo Clinic emphasizes that consistent preventive measures for autoimmune causes of encephalitis remain unavailable.<ref name="MayoPrevention">Mayo Clinic News Network. [https://newsnetwork.mayoclinic.org/discussion/types-of-encephalitis-a-mayo-clinic-expert-explains/ Types of encephalitis: A Mayo Clinic expert explains].</ref>

==Primary Prevention==
===Vaccination===
Autoimmune encephalitis has no specific preventive vaccine. Vaccines against selected infections can prevent some infectious causes of encephalitis, but should not be described as proven prevention of autoimmune encephalitis.<ref name="MayoPrevention" />

Autoimmune encephalitis patients who require immunosuppression may need vaccination review to reduce treatment-associated infection risk. This is a treatment-safety measure rather than prevention of a first autoimmune episode.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

===Cancer Risk Assessment===
Autoimmune encephalitis may be triggered by an associated neoplasm. Mayo Clinic advises discussing individual cancer risk and appropriate screening, because finding and treating a tumor early could potentially prevent some tumor-associated cases. This possibility should not be presented as a proven preventive strategy for all autoimmune encephalitis.<ref name="MayoCancer">Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/autoimmune-encephalitis/symptoms-causes/syc-20576380 Autoimmune encephalitis: Symptoms and causes].</ref>

Autoimmune encephalitis guidelines recommend targeted neoplasm investigation once the illness is suspected or diagnosed. This diagnostic workup is distinct from routine population cancer screening and does not establish a need for whole-body imaging in healthy people solely to prevent autoimmune encephalitis.<ref name="Hahn2024" />

See [[Autoimmune Encephalitis screening for an associated neoplasm|screening for an associated neoplasm]].

===Preventive Medication===
Autoimmune encephalitis guidelines describe immunotherapy for patients with a supported clinical diagnosis. They do not establish a prophylactic immunotherapy regimen for otherwise unaffected individuals.<ref name="Hahn2024" />

==Distinction from Secondary Prevention==
Autoimmune encephalitis relapse prevention may involve follow-up and selected maintenance immunotherapy after an initial episode. These measures belong to secondary prevention rather than primary prevention; the need for ongoing treatment varies by subtype and clinical course.<ref name="Abboud2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

See [[Autoimmune Encephalitis secondary prevention|secondary prevention]] and [[Autoimmune Encephalitis medical therapy|medical therapy]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis rehabilitation

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:07:17 GMT

← Older revision		Revision as of 12:07, 6 November 2026
Line 14:		Line 14:
	==Physical, Occupational, and Communication Rehabilitation==		==Physical, Occupational, and Communication Rehabilitation==
	Autoimmune encephalitis may require several complementary therapies:		Autoimmune encephalitis may require several complementary therapies:
	{\| class="wikitable" style="width:~~100~~%;"		{\| class="wikitable" style="width:80%;"
	\|-		\|-
	! Rehabilitation service		! Rehabilitation service

Autoimmune Encephalitis rehabilitation

Julinka Auta Fernandes — Fri, 06 Nov 2026 12:06:45 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis rehabilitation addresses physical, cognitive, communication, psychological, and participation difficulties after the acute illness. The 2024 Canadian consensus recommends screening for residual neuropsychiatric impairment and offering psychiatric care and neuropsychological rehabilitation when appropriate.<ref name="Hahn2024">Hahn C, Budhram A, A..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] rehabilitation addresses physical, cognitive, communication, psychological, and participation difficulties after the acute illness. The 2024 Canadian consensus recommends screening for residual neuropsychiatric impairment and offering psychiatric care and neuropsychological rehabilitation when appropriate.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

Autoimmune encephalitis rehabilitation complements continuing neurological treatment. Functional independence does not necessarily indicate complete recovery: a 2026 nationwide study found persistent cognitive deficits and fatigue despite favorable scores on the modified Rankin Scale, a measure of global disability.<ref name="Gaist2026">Gaist TA, Lodahl LR, Thorup HA, et al. [https://pubmed.ncbi.nlm.nih.gov/42636416/ Long-Term Outcomes in Autoimmune Encephalitis: A Nationwide, Clinical Study in Denmark]. ''Neurol Neuroimmunol Neuroinflamm''. 2026;13(5):e200641. doi:10.1212/NXI.0000000000200641. PMID:42636416.</ref>

==Assessment and Rehabilitation Planning==
Autoimmune encephalitis rehabilitation should be individualized to residual deficits, medical stability, and personal goals. Assess mobility, self-care, communication, cognition, mood, sleep, fatigue, and the support available at home. Use multidisciplinary review to decide between inpatient, outpatient, and community rehabilitation.<ref name="Abboud2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

==Physical, Occupational, and Communication Rehabilitation==
Autoimmune encephalitis may require several complementary therapies:
{| class="wikitable" style="width:100%;"
|-
! Rehabilitation service
! Main goals
|-
| Physical therapy
| Improve mobility, balance, coordination, transfers, and physical endurance according to impairment
|-
| Occupational therapy
| Restore daily activities, assess home or workplace adaptations, and support safe independence
|-
| Speech and language therapy
| Address language and communication difficulties and assess swallowing needs when present
|-
| Neuropsychology
| Characterize cognitive deficits and guide compensatory strategies and rehabilitation planning
|}
These services should be selected according to individual deficits rather than prescribed as an identical package for every patient.<ref name="Abboud2021" />

==Cognitive Rehabilitation==
Autoimmune encephalitis-related cognitive assessment should consider learning and memory, attention, processing speed, executive function, language, and visuospatial abilities. A brief bedside screen may miss clinically important impairment. Comprehensive neuropsychological testing can clarify difficulties and guide rehabilitation, with interpretation adjusted for age, education, language, fatigue, and clinical state.<ref name="Galioto2024">Galioto R, Grezmak T, Swetlik C, et al. [https://pubmed.ncbi.nlm.nih.gov/37949665/ Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review]. ''Neurol Neuroimmunol Neuroinflamm''. 2024;11(1):e200179. doi:10.1212/NXI.0000000000200179. PMID:37949665.</ref>

Autoimmune encephalitis rehabilitation may use practical compensatory approaches, such as reminders, written routines, and task simplification, selected by the rehabilitation team. Evidence has not established one superior disease-specific cognitive rehabilitation program.<ref name="Abboud2021" />

==Fatigue, Sleep, and Psychological Health==
Autoimmune encephalitis recovery requires assessment of fatigue and mood as well as cognitive performance. The 2026 Danish study found that fatigue and depressive symptoms were associated with life satisfaction; these outcomes therefore deserve attention even when physical disability is limited.<ref name="Gaist2026" />

Autoimmune encephalitis-related insomnia, anxiety, depression, emotional lability, and behavioral changes may require psychological or psychiatric care. Review whether medications or ongoing neurological symptoms interfere with participation in rehabilitation.<ref name="Hahn2024" /><ref name="Abboud2021" />

==Return to School, Work, and Community Activities==
Autoimmune encephalitis rehabilitation should address the cognitive and physical demands of school or employment. Consider a staged return, individualized workload, environmental adaptations, and reassessment as demands increase. Driving requires assessment of seizures, cognition, and applicable local licensing rules.<ref name="Abboud2021" />

Autoimmune encephalitis in children may produce persistent attention, memory, behavioral, and fatigue-related difficulties that affect educational achievement. Involve caregivers and teachers and arrange educational adjustments based on the child's assessed needs.<ref name="deBruijn2018">de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. [https://pubmed.ncbi.nlm.nih.gov/29703768/ Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis]. ''Neurology''. 2018;90(22):e1997–e2005. doi:10.1212/WNL.0000000000005605. PMID:29703768.</ref>

==Pediatric Rehabilitation==
Autoimmune encephalitis rehabilitation in children should account for developmental stage and changing educational expectations. For N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis, international consensus supports rehabilitation through services experienced in acquired brain injury. Improvement may continue for two years or longer, so early disability should not be treated as a fixed outcome.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

==Follow-Up and Evidence Limitations==
Autoimmune encephalitis follow-up should review daily function, cognition, mood, fatigue, participation, and caregiver concerns rather than relying on a single global disability score.<ref name="Gaist2026" /> Rehabilitation recommendations are supported mainly by expert consensus and observational evidence; optimal intensity, duration, and specific cognitive techniques remain uncertain.<ref name="Abboud2021" />

==Related Chapters==
* [[Autoimmune Encephalitis symptomatic and supportive therapy|Symptomatic and supportive therapy]].
* [[Autoimmune Encephalitis medical therapy|Medical therapy]].
* [[Autoimmune Encephalitis pediatric treatment considerations|Pediatric treatment considerations]].
* [[Autoimmune Encephalitis natural history, complications and prognosis|Natural history, complications and prognosis]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Rehabilitation]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis pediatric treatment considerations

Julinka Auta Fernandes — Fri, 06 Nov 2026 11:57:20 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis treatment in children requires pediatric neurology expertise, developmentally appropriate assessment, and individualized immunotherapy. The international pediatric treatment consensus specifically addresses N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis; its recommendations should not automatically be applied to every childhood infla..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] treatment in children requires pediatric neurology expertise, developmentally appropriate assessment, and individualized immunotherapy. The international pediatric treatment consensus specifically addresses N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis; its recommendations should not automatically be applied to every childhood inflammatory brain disorder.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

==When to Start Treatment==
Autoimmune encephalitis should be assessed urgently while infectious, metabolic, genetic, epileptic, and psychiatric alternatives are investigated. In a functionally impaired child meeting possible pediatric diagnostic criteria, immunotherapy may begin while antibody results are pending. Subsequent absence of antibodies and objective evidence of neuroinflammation should prompt diagnostic reassessment rather than automatic escalation.<ref name="Cellucci2020">Cellucci T, Van Mater H, Graus F, et al. [https://pubmed.ncbi.nlm.nih.gov/31953309/ Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient]. ''Neurol Neuroimmunol Neuroinflamm''. 2020;7(2):e663. doi:10.1212/NXI.0000000000000663. PMID:31953309.</ref>

Autoimmune encephalitis treatment should follow appropriate sampling and reasonable exclusion of infection. Empirical antiviral treatment is needed when herpes simplex encephalitis remains possible; immune treatment decisions require coordination with the infectious-diseases team.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.</ref>

==Pediatric NMDAR Antibody Encephalitis==
===First-Line Treatment===
Autoimmune encephalitis associated with NMDAR antibodies is initially treated with corticosteroids, preferably intravenous pulses. Add intravenous immunoglobulin (IVIG) or therapeutic plasma exchange in severe disease. Subsequent pulses, tapering, and treatment duration depend on response.<ref name="Nosadini2021" />

===Escalation and Maintenance===
Autoimmune encephalitis associated with NMDAR antibodies may require second-line rituximab when improvement is inadequate approximately two weeks after starting two or more first-line therapies. Assess the effect of second-line treatment over weeks; refractory cases may require further specialist-directed treatment after approximately 1–3 months, generally allowing more than six weeks. Maintenance immunosuppression beyond six months is usually unnecessary except with severe, prolonged, or relapsing disease. Recovery can be slow.<ref name="Nosadini2021" />

==Other Subtypes and Antibody-Negative Disease==
Autoimmune encephalitis without NMDAR antibodies requires treatment matched to the clinical syndrome, diagnostic certainty, and supporting investigations. Pediatric antibody-negative disease requires careful exclusion of mimics. Apparent improvement after corticosteroids alone does not confirm an autoimmune diagnosis.<ref name="Cellucci2020" />

==Drug and Procedural Safety==
Autoimmune encephalitis regimens in children require weight- or body-surface-area-based prescribing, maximum-dose checks, and specialist protocols; adult regimens must not simply be copied. Review the following treatment-specific risks:
* '''Corticosteroids:''' Infection, hyperglycemia, hypertension, sleep disruption, and behavioral effects.
* '''IVIG:''' Infusion reactions, thrombosis, and renal complications.
* '''Plasma exchange:''' Vascular-access complications, hypotension, electrolyte disturbance, and bleeding.
* '''Cyclophosphamide:''' Marrow suppression, infection, bladder toxicity, and potential gonadal injury.<ref name="Abboud2021" />

Autoimmune encephalitis treatment with rituximab requires hepatitis B screening, baseline blood counts, vaccination review, and monitoring for serious infection and infusion reactions.<ref name="RituximabLabel">Genentech. [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563 Rituxan (rituximab): prescribing information]. DailyMed, United States National Library of Medicine.</ref>

==Tumor-Directed Treatment==
Autoimmune encephalitis associated with pediatric NMDAR antibodies requires early tumor investigation and timely removal when an associated tumor is identified. Repeat investigation may be needed with poor response or relapse. Negative imaging does not establish a need for empirical removal of normal ovaries.<ref name="Nosadini2021" />

See [[Autoimmune Encephalitis screening for an associated neoplasm|screening for an associated neoplasm]] and [[Autoimmune Encephalitis surgery|surgery]].

==Supportive Care and Rehabilitation==
Autoimmune encephalitis may require seizure treatment, respiratory support, nutritional assistance, and management of agitation or autonomic instability alongside immunotherapy.<ref name="Abboud2021" /> Cognitive difficulties and fatigue can persist despite physical improvement; assess school participation and arrange neuropsychological and educational support.<ref name="deBruijn2018">de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. [https://pubmed.ncbi.nlm.nih.gov/29703768/ Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis]. ''Neurology''. 2018;90(22):e1997–e2005. doi:10.1212/WNL.0000000000005605. PMID:29703768.</ref>

==Evidence and Coordination of Care==
Autoimmune encephalitis treatment recommendations largely reflect observational evidence and expert consensus. A 2024 single-center study associated implementation of a pediatric clinical pathway with shorter time to investigation and treatment; it does not establish a universal regimen or prove comparative drug efficacy.<ref name="Barter2024">Barter KM, Fuchs C, Graham TB, Pagano LM, Vater M. [https://pubmed.ncbi.nlm.nih.gov/38173540/ Anti-NMDAR Encephalitis Clinical Practice Guideline: Improving Time to Diagnosis, Treatment, and Hospital Length of Stay]. ''Neurol Clin Pract''. 2024;14(1):e200218. doi:10.1212/CPJ.0000000000200218. PMID:38173540.</ref>

==Related Chapters==
* [[Autoimmune Encephalitis pediatric considerations|Pediatric considerations]]: presentation and diagnostic assessment.
* [[Autoimmune Encephalitis medical therapy|Medical therapy]]: general treatment framework.
* [[Autoimmune Encephalitis interventions|Interventions]]: procedural treatment.
* [[Autoimmune Encephalitis symptomatic and supportive therapy|Symptomatic and supportive therapy]]: symptom management and rehabilitation.

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Pediatrics]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis interventions

Julinka Auta Fernandes — Fri, 06 Nov 2026 11:49:32 GMT

Treatment Course

← Older revision		Revision as of 11:49, 6 November 2026
(3 intermediate revisions by the same user not shown)
Line 15:		Line 15:

	Autoimmune encephalitis treatment sequencing requires coordination because plasma exchange can remove recently administered immunoglobulin or therapeutic antibodies. Schedule IVIG and antibody-based medicines with the treating neurology and apheresis teams.<ref name="AbboudAcute2021" />		Autoimmune encephalitis treatment sequencing requires coordination because plasma exchange can remove recently administered immunoglobulin or therapeutic antibodies. Schedule IVIG and antibody-based medicines with the treating neurology and apheresis teams.<ref name="AbboudAcute2021" />

			[[File:960px-Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg\|thumb\|center\|350px\|'''Plasma removed during therapeutic plasma exchange in a patient with autoimmune encephalitis.''' Photograph by NotSB10, via Wikimedia Commons, licensed under [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution–ShareAlike 4.0].<ref name="PlasmaExchangeImage">NotSB10. [https://commons.wikimedia.org/wiki/File:Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg Plasma from patient with autoimmune encephalitis removed by PLEX]. Photograph taken May 28, 2021. Wikimedia Commons. Own work; Creative Commons Attribution–ShareAlike 4.0.</ref>]]

	===Risks and Monitoring===		===Risks and Monitoring===
Line 23:		Line 25:
	* Catheter-associated infection or thrombosis.		* Catheter-associated infection or thrombosis.
	* Difficulty completing treatment in patients with severe agitation or autonomic instability.<ref name="AbboudAcute2021" />		* Difficulty completing treatment in patients with severe agitation or autonomic instability.<ref name="AbboudAcute2021" />
	[[File:960px-Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg\|thumb\|center\|350px\|'''Plasma removed during therapeutic plasma exchange in a patient with autoimmune encephalitis.''' Plasma exchange removes circulating antibodies and other inflammatory mediators. Photograph by NotSB10, Wikimedia Commons; licensed under Creative Commons Attribution–ShareAlike 4.0.<ref name="PlasmaExchangeImage">NotSB10. [https://commons.wikimedia.org/wiki/File:Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg Plasma from patient with autoimmune encephalitis removed by PLEX]. Photograph taken May 28, 2021. Wikimedia Commons. Licensed under Creative Commons Attribution–ShareAlike 4.0.</ref>]]


Line 50:		Line 52:

	==Associated Tumor Management==		==Associated Tumor Management==
	Autoimmune encephalitis associated with a relevant neoplasm requires prompt specialist evaluation for tumor treatment, including resection when appropriate. Tumor-directed treatment should be coordinated with immunotherapy rather than deferred until neurological recovery.<ref name="Hahn2024" />		Autoimmune encephalitis associated with a relevant neoplasm requires prompt specialist evaluation for tumor treatment, including resection when appropriate. Tumor-directed treatment should be coordinated with immunotherapy rather than deferred until neurological recovery.<ref name="Hahn2024" />l



	~~See~~ [[Autoimmune Encephalitis screening for an associated neoplasm\|screening for an associated neoplasm~~]] and [[Autoimmune Encephalitis surgery\|surgery~~]].		For tumor-directed surgery, see [[Autoimmune Encephalitis surgery\|surgery]]. For investigation of an underlying tumor, see [[Autoimmune Encephalitis screening for an associated neoplasm\|screening for an associated neoplasm]].

	==Follow-Up==		==Follow-Up==

Autoimmune Encephalitis surgery

Julinka Auta Fernandes — Fri, 06 Nov 2026 11:42:50 GMT

← Older revision	Revision as of 11:42, 6 November 2026
(One intermediate revision by the same user not shown)
(No difference)

Autoimmune Encephalitis interventions

Julinka Auta Fernandes — Fri, 06 Nov 2026 11:38:43 GMT

← Older revision		Revision as of 11:38, 6 November 2026
(2 intermediate revisions by the same user not shown)
Line 23:		Line 23:
	* Catheter-associated infection or thrombosis.		* Catheter-associated infection or thrombosis.
	* Difficulty completing treatment in patients with severe agitation or autonomic instability.<ref name="AbboudAcute2021" />		* Difficulty completing treatment in patients with severe agitation or autonomic instability.<ref name="AbboudAcute2021" />
			[[File:960px-Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg\|thumb\|center\|350px\|'''Plasma removed during therapeutic plasma exchange in a patient with autoimmune encephalitis.''' Plasma exchange removes circulating antibodies and other inflammatory mediators. Photograph by NotSB10, Wikimedia Commons; licensed under Creative Commons Attribution–ShareAlike 4.0.<ref name="PlasmaExchangeImage">NotSB10. [https://commons.wikimedia.org/wiki/File:Plasma_from_patient_with_autoimmune_encephalitis_removed_by_PLEX.jpg Plasma from patient with autoimmune encephalitis removed by PLEX]. Photograph taken May 28, 2021. Wikimedia Commons. Licensed under Creative Commons Attribution–ShareAlike 4.0.</ref>]]


	==Respiratory Interventions==		==Respiratory Interventions==

Autoimmune Encephalitis medical therapy

Julinka Auta Fernandes — Fri, 06 Nov 2026 11:34:45 GMT

Show changes

Autoimmune Encephalitis surgery

Julinka Auta Fernandes — Fri, 06 Nov 2026 07:44:27 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is primarily treated medically, but removal of an associated tumor can be an important component of treatment. Surgery is directed at the relevant neoplasm or a specific complication, rather than routine removal of brain tissue.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune ence..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] is primarily treated medically, but removal of an associated tumor can be an important component of treatment. Surgery is directed at the relevant neoplasm or a specific complication, rather than routine removal of brain tissue.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.</ref>

==Surgery==
===Resection of an Associated Tumor===
Autoimmune encephalitis associated with a relevant, resectable neoplasm warrants prompt surgical and oncological assessment. Tumor treatment should proceed alongside immunotherapy when feasible. The operation depends on tumor location, histology, stage, and patient stability; not every associated malignancy is treated surgically.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

===Ovarian Teratoma Resection===
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies and an ovarian teratoma requires gynecological assessment for tumor removal. Where oncologically appropriate, favor an approach that removes the lesion while preserving ovarian function and fertility. The extent of surgery should reflect lesion characteristics rather than encephalitis severity alone.<ref name="Iyengar2022">Iyengar Y, Hébert J, Climans SA, et al. [https://pubmed.ncbi.nlm.nih.gov/36468045/ Ovarian resection in anti-N-methyl-D-aspartate receptor encephalitis: A comparison of surgical approaches]. ''Front Neurol''. 2022;13:1043785. doi:10.3389/fneur.2022.1043785. PMID:36468045.</ref>

Autoimmune encephalitis does not necessarily resolve immediately after tumor removal. Continue neurological treatment and rehabilitation according to clinical response.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

===Imaging-Negative Disease and Oophorectomy===
Autoimmune encephalitis with negative ovarian imaging does not routinely justify empirical bilateral oophorectomy. The Canadian consensus describes this as controversial, with weak evidence and irreversible fertility and endocrine consequences. Some guideline authors oppose offering it at all. Any exceptional consideration requires specialist multidisciplinary review of persistently life-threatening disease despite second- and third-line treatment, repeated multimodal pelvic imaging, cerebrospinal fluid confirmation of NMDAR antibodies, and legally valid informed consent. It is not recommended by that consensus outside ages 18–45.<ref name="Hahn2024" />

Autoimmune encephalitis surgical evidence remains limited: a small retrospective comparison found no demonstrated functional advantage from aggressive ovarian resection. Its observational design and differences between patient groups preclude definitive causal conclusions. The authors favored function-preserving surgery for an imaging-confirmed or suspected teratoma and repeated imaging when initial investigations were negative.<ref name="Iyengar2022" />

===Brain Biopsy===
Autoimmune encephalitis generally does not require brain biopsy when the presentation and investigations are typical. Targeted biopsy may be considered for atypical or mass-like lesions when an alternative diagnosis, such as malignancy, remains unresolved. Histological findings can be nonspecific; biopsy is not a routine confirmatory test for autoimmune encephalitis.<ref name="Abboud2021" />

===Procedures for Complications===
Autoimmune encephalitis with prolonged respiratory or feeding impairment may require tracheostomy or gastrostomy. These procedures support care rather than treat the underlying immune process. Decisions should reflect the anticipated course and multidisciplinary assessment.<ref name="AbboudLong2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

See [[Autoimmune Encephalitis interventions|interventions]].

==Indications==
Autoimmune encephalitis-related indications for surgical assessment include:
* A relevant neoplasm for which resection is appropriate.
* An unresolved atypical brain lesion requiring tissue diagnosis.
* Prolonged airway or nutritional support needs requiring a procedure.<ref name="Hahn2024" /><ref name="Abboud2021" /><ref name="AbboudLong2021" />

==Contraindications and Limitations==
Autoimmune encephalitis has no single procedure-independent list of surgical contraindications. Assess anesthetic risk, respiratory compromise, dysautonomia, infection, bleeding risk, and the proposed operation's expected benefit. Severe neurological impairment alone should not automatically exclude potentially beneficial tumor treatment.<ref name="Abboud2021" /><ref name="Nosadini2021" />

Autoimmune encephalitis without an identified surgical target is not an indication for routine exploratory surgery or removal of normal ovaries.<ref name="Iyengar2022" />

==Pediatric Considerations==
Autoimmune encephalitis in children requires pediatric neurology and appropriate surgical expertise. The pediatric NMDAR consensus emphasizes early tumor investigation and timely removal when a tumor is identified. Negative initial imaging may require reassessment, especially with poor response or relapse; it does not establish a need for empirical ovarian removal.<ref name="Nosadini2021" />

==Postoperative Care==
Autoimmune encephalitis requires continued immunotherapy assessment, seizure and autonomic monitoring, rehabilitation, and tumor-specific follow-up after surgery. Review histopathology and coordinate subsequent care with the relevant surgical and oncology teams.<ref name="Hahn2024" /><ref name="AbboudLong2021" />

See [[Autoimmune Encephalitis medical therapy|medical therapy]], [[Autoimmune Encephalitis symptomatic and supportive therapy|symptomatic and supportive therapy]], and [[Autoimmune Encephalitis screening for an associated neoplasm|screening for an associated neoplasm]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis interventions

Julinka Auta Fernandes — Fri, 06 Nov 2026 07:33:38 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis may require therapeutic plasma exchange and procedures to manage respiratory failure, severe autonomic dysfunction, nutritional difficulties, or refractory catatonia. Interventions are selected according to disease severity and complications and should accompany appropriate immunotherapy and treatment of an associated neoplasm.<ref name="AbboudAc..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] may require therapeutic plasma exchange and procedures to manage respiratory failure, severe autonomic dysfunction, nutritional difficulties, or refractory catatonia. Interventions are selected according to disease severity and complications and should accompany appropriate immunotherapy and treatment of an associated neoplasm.<ref name="AbboudAcute2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.</ref>

==Therapeutic Plasma Exchange==
===Indications===
Autoimmune encephalitis may be treated with [[therapeutic plasma exchange]] (TPE), also commonly abbreviated PLEX. The procedure removes circulating antibodies and other inflammatory mediators. The 2024 Canadian consensus recommends high-dose corticosteroids combined with either plasma exchange or intravenous immunoglobulin (IVIG) for severe adult disease. Plasma exchange is a first-line option rather than exclusively a rescue treatment.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

===Treatment Course===
Autoimmune encephalitis treatment protocols vary. The Canadian consensus describes five exchanges on alternate days over approximately ten days in adults. The apheresis team individualizes vascular access, exchange volume, replacement fluid, and treatment frequency.<ref name="Hahn2024" />

Autoimmune encephalitis treatment sequencing requires coordination because plasma exchange can remove recently administered immunoglobulin or therapeutic antibodies. Schedule IVIG and antibody-based medicines with the treating neurology and apheresis teams.<ref name="AbboudAcute2021" />

===Risks and Monitoring===
Autoimmune encephalitis patients undergoing plasma exchange require assessment of hemodynamic stability, bleeding risk, vascular access, and ability to tolerate the procedure. Important complications include:
* Hypotension and fluid shifts.
* Electrolyte disturbances.
* Bleeding or coagulation abnormalities.
* Catheter-associated infection or thrombosis.
* Difficulty completing treatment in patients with severe agitation or autonomic instability.<ref name="AbboudAcute2021" />

==Respiratory Interventions==
Autoimmune encephalitis can cause central hypoventilation, reduced consciousness, and impaired airway protection. Endotracheal intubation and mechanical ventilation may be necessary when breathing or airway protection is inadequate. Severe dysautonomia or refractory status epilepticus may also require intensive-care management.<ref name="AbboudAcute2021" />

Autoimmune encephalitis with prolonged ventilatory dependence may require consideration of [[tracheostomy]]. The decision depends on the anticipated course, airway needs, and overall condition; no fixed autoimmune encephalitis-specific timing applies to every patient.<ref name="AbboudLong2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

==Cardiac Monitoring and Pacing==
Autoimmune encephalitis-associated dysautonomia may cause marked heart-rate fluctuations, severe bradycardia, or asystole. Patients with clinically significant rhythm disturbances require continuous cardiac monitoring and urgent cardiology and intensive-care assessment.<ref name="AbboudLong2021" />

Autoimmune encephalitis with recurrent, life-threatening bradyarrhythmias may require temporary or, in selected cases, permanent pacing. Pacing is not routine treatment for uncomplicated sinus tachycardia or an isolated abnormal electrocardiogram. The potential reversibility of autonomic dysfunction should inform device selection and follow-up.<ref name="AbboudLong2021" />

==Nutritional Support==
Autoimmune encephalitis may impair swallowing, awareness, or the ability to maintain adequate intake. Swallowing assessment, aspiration precautions, and dietetic review guide the need for enteral feeding. Nasogastric feeding or gastrostomy may be considered according to expected duration and clinical circumstances.<ref name="AbboudLong2021" />

==Electroconvulsive Therapy==
Autoimmune encephalitis complicated by severe, treatment-resistant catatonia may warrant consideration of [[electroconvulsive therapy]] (ECT). The Canadian consensus describes its use in selected refractory cases; evidence is predominantly observational rather than derived from randomized trials.<ref name="Hahn2024" />

Autoimmune encephalitis treatment with ECT requires coordinated assessment by psychiatry, neurology, and anesthesia, particularly when seizures, autonomic instability, or respiratory compromise are present. ECT addresses selected neuropsychiatric complications and does not replace disease-directed immunotherapy.<ref name="Hahn2024" />

==Interventions in Children==
Autoimmune encephalitis in children requires pediatric procedural expertise and age-appropriate monitoring. For N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis, international consensus includes plasma exchange among first-line treatments, particularly in severe disease. Vascular access, hemodynamic tolerance, agitation, and procedural burden influence its feasibility.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

See [[Autoimmune Encephalitis pediatric considerations|pediatric considerations]].

==Associated Tumor Management==
Autoimmune encephalitis associated with a relevant neoplasm requires prompt specialist evaluation for tumor treatment, including resection when appropriate. Tumor-directed treatment should be coordinated with immunotherapy rather than deferred until neurological recovery.<ref name="Hahn2024" />

See [[Autoimmune Encephalitis screening for an associated neoplasm|screening for an associated neoplasm]] and [[Autoimmune Encephalitis surgery|surgery]].

==Follow-Up==
Autoimmune encephalitis interventions require repeated assessment as neurological function improves. Review continuing needs for vascular access, ventilatory support, feeding tubes, and cardiac devices, while monitoring for procedural complications. Rehabilitation and multidisciplinary discharge planning remain essential.<ref name="AbboudLong2021" />

For additional management, see [[Autoimmune Encephalitis medical therapy|medical therapy]] and [[Autoimmune Encephalitis symptomatic and supportive therapy|symptomatic and supportive therapy]].

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]

Autoimmune Encephalitis symptomatic and supportive therapy

Julinka Auta Fernandes — Fri, 06 Nov 2026 07:25:01 GMT

Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis requires symptomatic and supportive treatment alongside immunotherapy and treatment of an associated tumor. Care aims to control seizures and distress, prevent complications, and restore function. Symptomatic improvement alone does not establish that inflammation has resolved.<ref name="AbboudLong2021">Abboud H, Probasco J, Irani SR, et al. [http..."

New page

__NOTOC__
{{CMG}}
{{AE}} {{JAF}}
{{Autoimmune encephalitis}}

==Overview==
[[Autoimmune Encephalitis|Autoimmune encephalitis]] requires symptomatic and supportive treatment alongside immunotherapy and treatment of an associated tumor. Care aims to control seizures and distress, prevent complications, and restore function. Symptomatic improvement alone does not establish that inflammation has resolved.<ref name="AbboudLong2021">Abboud H, Probasco J, Irani SR, et al. [https://pubmed.ncbi.nlm.nih.gov/33649021/ Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.</ref>

For disease-directed treatment, see [[Autoimmune Encephalitis medical therapy|medical therapy]].

==Seizures and Status Epilepticus==
Autoimmune encephalitis-associated seizures generally require antiseizure medicines together with prompt immunotherapy. Drug choice should account for seizure type, behavioral adverse effects, interactions, and organ function. After recovery, continued antiseizure treatment should be individualized; not every patient requires lifelong treatment.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10.1017/cjn.2024.16 Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults]. ''Can J Neurol Sci''. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.</ref>

Autoimmune encephalitis with [[status epilepticus]] requires emergency treatment and escalation according to established seizure protocols. Continuous [[electroencephalography]] (EEG) is useful when consciousness remains impaired after seizures, nonconvulsive seizures are suspected, or intravenous anesthetic treatment requires monitoring. Video-EEG can help distinguish seizures from dyskinesias and autonomic spells; clinical appearance alone may be misleading.<ref name="Herman2015">Herman ST, Abend NS, Bleck TP, et al. [https://pubmed.ncbi.nlm.nih.gov/25626778/ Consensus statement on continuous EEG in critically ill adults and children, part I: indications]. ''J Clin Neurophysiol''. 2015;32(2):87–95. doi:10.1097/WNP.0000000000000166. PMID:25626778.</ref>

==Agitation, Psychosis, and Catatonia==
Autoimmune encephalitis-related behavioral disturbance should be managed with a calm environment, reduced overstimulation, familiar caregivers, and assessment for pain, infection, medication effects, and sleep disruption. Minimize physical restraint when feasible.<ref name="Hahn2024" />

* '''Antipsychotics:''' Use cautiously, particularly in N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis. Worsening movements, rigidity, fever, or autonomic instability requires reassessment for adverse drug reactions, including neuroleptic malignant syndrome.
* '''Catatonia:''' Benzodiazepines may help, but require caution with hypoventilation or reduced alertness. Severe refractory catatonia may warrant electroconvulsive therapy through specialist psychiatry, neurology, and anesthesia assessment.<ref name="Hahn2024" />

==Movement Disorders, Sleep, and Mood==
Autoimmune encephalitis-related movement disorders may need targeted treatment when they cause injury, pain, exhaustion, or interfere with care. Balance benefit against sedation and respiratory effects. Restore a regular sleep–wake schedule and address persistent insomnia, anxiety, depression, or emotional lability. Symptomatic drugs should be reviewed as recovery progresses.<ref name="AbboudLong2021" />

==Autonomic and Respiratory Support==
Autoimmune encephalitis can cause central hypoventilation, impaired airway protection, and major fluctuations in heart rate, blood pressure, and temperature. Severe cases require intensive care, respiratory support, and continuous physiological monitoring. Clinically important bradyarrhythmias or asystole require urgent specialist management. Sedatives may worsen breathing and obscure neurological assessment.<ref name="AbboudAcute2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management]. ''J Neurol Neurosurg Psychiatry''. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.</ref>

==Fluids, Electrolytes, and General Care==
Autoimmune encephalitis care includes monitoring fluid balance and electrolytes. Hyponatremia is particularly associated with leucine-rich glioma-inactivated protein 1 (LGI1) antibody encephalitis. Evaluate the cause and correct safely; avoid rapid overcorrection.<ref name="AbboudAcute2021" />

Autoimmune encephalitis with dysphagia, reduced consciousness, or immobility requires individualized multidisciplinary care:
* Assess swallowing and aspiration risk; provide appropriate nutritional support.
* Review venous thromboembolism prevention, skin care, positioning, and mobilization.
* Identify infections, urinary or bowel problems, and pain that may worsen agitation or delay recovery.<ref name="AbboudAcute2021" /><ref name="AbboudLong2021" />

==Rehabilitation and Follow-Up==
Autoimmune encephalitis recovery may require physical, occupational, speech and language, psychological, and neuropsychological rehabilitation. Assess memory, attention, executive function, fatigue, mood, and daily independence. Plan a gradual return to work or education and discuss driving according to local rules.<ref name="AbboudLong2021" />

Autoimmune encephalitis in children may leave cognitive and fatigue-related difficulties despite good physical recovery. Coordinate school support with caregivers and teachers; educational demands can reveal persistent deficits.<ref name="deBruijn2018">de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. [https://pubmed.ncbi.nlm.nih.gov/29703768/ Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis]. ''Neurology''. 2018;90(22):e1997–e2005. doi:10.1212/WNL.0000000000005605. PMID:29703768.</ref> The pediatric NMDAR consensus emphasizes rehabilitation in a service familiar with acquired brain injury; improvement may continue for two years or longer.<ref name="Nosadini2021">Nosadini M, Thomas T, Eyre M, et al. [https://pubmed.ncbi.nlm.nih.gov/34301820/ International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis]. ''Neurol Neuroimmunol Neuroinflamm''. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.</ref>

==Reassessment and Evidence Limitations==
Autoimmune encephalitis-related deterioration should prompt reassessment for relapse, seizures, infection, metabolic disturbance, and treatment toxicity. Much symptomatic treatment rests on expert consensus and observational evidence; management must be adapted to the patient rather than a fixed drug sequence.<ref name="Hahn2024" /><ref name="AbboudLong2021" />

==References==
{{reflist|2}}

[[Category:Neurology]]
[[Category:Autoimmune diseases]]